Study of Multiple Doses of Saxagliptin (BMS-477118)
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the positive efficacy trend among doses of saxagliptin (BMS-477118) in subjects
with Type 2 diabetes mellitus by assessing the change from baseline in HbA1c following 12
weeks of double-blind treatment.